Cabozantinib associated with excessive toxicity for salivary gland cancer in phase II trial

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2022年 / 1887卷 / 1期
关键词：
D O I：
10.1007/s40278-022-07674-3
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9 / 9
相关论文
共 50 条
  • [1] Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer
    van Boxtel, Wim
    Uijen, Maike J. M.
    Krens, Stefanie D.
    Dijkema, Tim
    Willems, Stefan M.
    Jonker, Marianne A.
    Pegge, Sjoert A. H.
    van Engen-van Grunsven, Adriana C. H.
    van Herpen, Carla M. L.
    EUROPEAN JOURNAL OF CANCER, 2022, 161 : 128 - 137
  • [2] A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.
    van Boxtel, Wim
    Uijen, Maike
    Driessen, Chantal
    Pegge, Sjoert
    Willems, Stefan M.
    Jonker, Marianne
    Dijkema, Tim
    van Engen-van Grunsven, Ilse
    Van Herpen, Carla M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer
    Krens, Stefanie D.
    van Boxtel, Wim
    Uijen, Maike J. M.
    Jansman, Frank G. A.
    Desar, Ingrid M. E.
    Mulder, Sasja F.
    van Herpen, Carla M. L.
    van Erp, Nielka P.
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (02) : 308 - 316
  • [4] Phase II trial of gefitinib inpatients with incurable salivary gland cancer.
    Glisson, BS
    Blumenschein, G
    Francisco, M
    Erasmus, J
    Zinner, R
    Kies, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 508S - 508S
  • [5] Exposure-toxicity analysis of cabozantinib in patients with salivary gland cancer and renal cell cancer.
    Krens, Stefanie D.
    van Boxtel, Wim
    Uijen, Maike J.
    Jansman, Frank G.
    Desar, Ingrid M.
    Mulder, Sasja F.
    van Herpen, Carla M.
    van Erp, Nielka P.
    CANCER RESEARCH, 2021, 81 (13)
  • [6] Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.
    Kim, Youjin
    Lee, Su Jin
    Park, Keunchil
    Lee, Se-hoon
    Sun, Jong Mu
    Keam, Bhumsuk
    An, Ho Jung
    Cho, Jae Yong
    Kim, Jin-Soo
    Lee, Ha-young
    Kim, HyeRyun
    Lee, Kyoung Eun
    Choi, Moon Young
    Lee, Ki Hyeong
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] A phase II umbrella clinical trial of advanced salivary gland cancer based on molecular typing
    Ji, Dongmei
    Guo, Yanjing
    Liu, Xin
    Yang, Yanan
    Sang, Youzhou
    Chen, Guangliang
    Dong, Shu
    Wang, Yulong
    He, Xiayun
    Ying, Hongmei
    Lu, Xueguan
    Wang, Yu
    Hu, Chaosu
    Ji, Qinghai
    Zhang, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer
    Nagatani, Yoshiaki
    Kiyota, Naomi
    Yamazaki, Tomoko
    Asada, Yukinori
    Higashino, Masaaki
    Goto, Masahiro
    Satake, Hironaga
    Ota, Ichiro
    Uemura, Hirokazu
    Yane, Katsunari
    Tanaka, Kaoru
    Onoe, Takuma
    Iwae, Shigemichi
    Hirano, Shigeru
    Imamura, Yoshinori
    Kimbara, Shiro
    Nose, Taku
    Koyama, Taiji
    Funakoshi, Yohei
    Minami, Hironobu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Phase II trial of eribulin for recurrent or metastatic salivary gland cancers.
    Eaton, Keith D.
    Goulart, Bernardo H. L.
    Santana-Davila, Rafael
    Chow, Laura Quan Man
    Wood, Rebecca L.
    Rodriguez, Cristina P.
    Baik, Christina S.
    Martins, Renato G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies
    Rodriguez, Cristina P.
    Martins, Renato G.
    Baik, Christina
    Chow, Laura Q.
    Santana-Davila, Rafael
    Goulart, Bernardo H.
    Lee, Sylvia
    Eaton, Keith D.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2018, 40 (03): : 584 - 589
12345